← Back to patent-cliff list
CAS 153011-57-5
(S)-2-(3-oxo-1,4-dioxaspiro[4.5]decan-2-yl)acetic acid
Codes: IXAB-062, ORLI-003
Application context (from source-drug indications)
Breast cancerIxabepiloneMetastatic breast cancerIxabepiloneCervical cancerIxabepiloneProstate cancerIxabepiloneSolid tumourIxabepiloneNeutropeniaIxabepiloneObesityOrlistatI型高脂蛋白血症OrlistatHypertriglyceridaemiaOrlistat女性不孕OrlistatDiabetesOrlistatObstructive sleep apnoea syndromeOrlistat
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ixabepilone | Tier C — Watch / trade | - |
| Orlistat | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(4S,7R,8S,9S,16S,Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→4-((S,1E,5Z)-3-azido-6-iodo-2-methylhepta-1,5-dien-1-yl)-2-methylthiazole→(S)-2-hydroxysuccinic acid→(S)-2-(3-oxo-1,4-dioxaspiro[4.5]decan-2-yl)acetic acid→(S)-3-hydroxydihydrofuran-2(3H)-one→(S)-3-((tert-butyldimethylsilyl)oxy)dihydrofuran-2(3H)-one→(S)-3,5-bis((tert-butyldimethylsilyl)oxy)pentan-2-one→diethyl ((2-methylthiazol-4-yl)methyl)phosphonate→(S,E)-4-(3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylpent-1-en-1-yl)-2-methylthiazole→(S,E)-3-((tert-butyldimethylsilyl)oxy)-4-methyl-5-(2-methylthiazol-4-yl)pent-4-en-1-ol→(S,E)-3-((tert-butyldimethylsilyl)oxy)-4-methyl-5-(2-methylthiazol-4-yl)pent-4-enal→4-((S,1E,5Z)-3-((tert-butyldimethylsilyl)oxy)-6-iodo-2-methylhepta-1,5-dien-1-yl)-2-methylthiazole→(S,1E,5Z)-6-iodo-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-ol→tert-butyl (3R,6R,7S,8S)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8-tetramethyl-5-oxoundec-10-enoate→tert-butyl (6R,7S,8S,12Z,15S,16E)-15-azido-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoate→tert-butyl (6R,7S,8S,12Z,15S,16E)-15-((tert-butoxycarbonyl)amino)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoate→tert-butyl (6R,7S,8S,12Z,15S,16E)-15-((tert-butoxycarbonyl)amino)-7-((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-3,5-dioxoheptadeca-12,16-dienoate→tert-butyl (3S,6R,7S,8S,12Z,15S,16E)-15-amino-7-((tert-butyldimethylsilyl)oxy)-3-hydroxy-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoate→4-(chloromethyl)-2-methylthiazole hydrochloride→5-(benzyloxy)pentanal→pivaloyl chloride→(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol→5-(benzyloxy)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylpentanamide→(S)-5-(benzyloxy)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N,2-dimethylpentanamide→(S)-5-(benzyloxy)-2-methylpentan-1-ol→(S)-5-(benzyloxy)-2-methylpentanal→(S)-4-benzyl-3-propionyloxazolidin-2-one→(R)-4-benzyl-3-((2R,3S,4S)-7-(benzyloxy)-3-hydroxy-2,4-dimethylheptanoyl)oxazolidin-2-one→N,O-dimethylhydroxylamine hydrochloride→(2R,3S,4S)-7-(benzyloxy)-3-hydroxy-N-methoxy-N,2,4-trimethylheptanamide→(2R,3S,4S)-7-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-N-methoxy-N,2,4-trimethylheptanamide→(2R,3S,4S)-7-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-2,4-dimethylheptanal→(2-methylbut-3-en-2-yl)magnesium chloride→(5R,6S,7S)-10-(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)-3,3,5,7-tetramethyldec-1-en-4-one→(4R,5S,6S)-9-(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-2,2,4,6-tetramethyl-3-oxononanal→tert-butyl (3R,6R,7S,8S)-11-(benzyloxy)-7-((tert-butyldimethylsilyl)oxy)-3-hydroxy-4,4,6,8-tetramethyl-5-oxoundecanoate→tert-butyl (3R,6R,7S,8S)-11-(benzyloxy)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8-tetramethyl-5-oxoundecanoate→tert-butyl (3R,6R,7S,8S)-3,7-bis((tert-butyldimethylsilyl)oxy)-11-hydroxy-4,4,6,8-tetramethyl-5-oxoundecanoate
(S)-2-hydroxysuccinic acid→cyclohexanone→(S)-2-(3-oxo-1,4-dioxaspiro[4.5]decan-2-yl)acetic acid→(S)-3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-1,4-dioxaspiro[4.5]decan-2-one→(S)-methyl 4-((tert-butyldiphenylsilyl)oxy)-2-hydroxybutanoate→ORLI-006→(S)-tert-butyl(2-(oxiran-2-yl)ethoxy)diphenylsilane→1-bromodecane→(R)-1-((tert-butyldiphenylsilyl)oxy)tetradecan-3-ol→benzyl 2,2,2-trichloroacetimidate→(R)-((3-(benzyloxy)tetradecyl)oxy)(tert-butyl)diphenylsilane→(R)-3-(benzyloxy)tetradecan-1-ol→(R)-3-(benzyloxy)tetradecanal→(E)-trimethyl(non-2-en-1-yl)silane→(7R,8S,10R)-10-(benzyloxy)-7-vinylhenicosan-8-ol→(((7R,8S,10R)-10-(benzyloxy)-7-vinylhenicosan-8-yl)oxy)(tert-butyl)dimethylsilane→(2S,3S,5R)-5-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-2-hexylhexadecanoic acid→(2S,3S,5R)-5-(benzyloxy)-2-hexyl-3-hydroxyhexadecanoic acid→(3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyloxetan-2-one→(3S,4S)-3-hexyl-4-((R)-2-hydroxytridecyl)oxetan-2-one→(S)-2-formamido-4-methylpentanoic acid
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.